WASHINGTON — Mallinckrodt Pharmaceuticals has become a member of the National Pharmaceutical Council (NPC).
Dan Leonard, NPC
The health policy research organization said Thursday that Steven Romano, senior vice president and chief scientific officer at Mallinckrodt, will serve as the company’s representative on the NPC board of directors.
“We are pleased that Mallinckrodt has joined us in support of our efforts to conduct research and educational activities on important health policy issues such as real-world evidence, how heath care is valued and accessed, and biopharmaceutical innovation,” stated NPC president Dan Leonard. “We welcome Dr. Romano’s expertise on our board and are looking forward to his involvement with NPC.”
A global organization, Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products.
The company’s focus areas include autoimmune and rare diseases in specialty areas such as neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.
In becoming an NPC member, Mallinckrodt joins other biopharmaceutical companies, including AbbVie, Allergan, Amgen, Astellas Pharma US, AstraZeneca, Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Johnson & Johnson, Merck, Novartis, Pfizer, Purdue Pharma, Sanofi, Takeda Pharmaceuticals USA and Teva Pharmaceuticals.
